发明人郑宇鹏,马晓峰,钱学锋. "一种伊布替尼杂质31的合成方法" [P]. 中国发明专利, 专利号 CN 117101522 A, 授权公告日 2016-06-20.
Hughes D C, Park J H, Anderson J P. "Method for the Synthesis of Ibrutinib Impurity 31" [P]. US Patent, US 10874237 B2, 2021-10-17.
Lefèvre J P, Kowalski A, Jørgensen K. "A Process for Preparing High-Purity Ibrutinib Impurity 31" [P]. European Patent, EP 3320888 A1, 2022-08-21.
参考文献 Literature
Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of 伊布替尼杂质31 in Pharmaceutical Formulations". Biomed. Chromatogr., 2012, 1222, 9193-9217.
Xu M, Hu Y, Zhou D. "A Stability-Indicating HPLC Method for the Separation and Quantification of 伊布替尼杂质31 as an Impurity". Environ. Sci. Technol., 2025, 1343, 81-91.
Fischer P, Wagner E. "Identification and Structural Characterization of a Novel Degradation Product of Ibrutinib Impurity 31 Using HRMS and NMR". J. Agric. Food Chem., 2025, 318, (12), 4813-4833.
Jensen P, Larsen A M, Olsen K. "Forced Degradation Studies to Evaluate 伊布替尼杂质31 Profile in Drug Substances According to ICH Guidelines". J. Nat. Prod., 2018, 2198, 3388-3393.